GHRP-2: A Comprehensive Research Monograph

Overview

GHRP-2 (Growth Hormone Releasing Peptide-2), also designated Pralmorelin or KP-102, is a synthetic hexapeptide with the amino acid sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 and a molecular weight of approximately 818.01 g/mol. It belongs to the family of growth hormone secretagogues (GHS), a class of synthetic compounds that stimulate the release of growth hormone (GH) from the anterior pituitary. GHRP-2 was developed by Cyril Y. Bowers and colleagues at Tulane University through systematic structure-activity optimization of early GH-releasing peptides, and it is widely considered the most potent member of the hexapeptide GHS family in terms of GH-releasing activity.

The development of GHRP-2 and related peptides played a pivotal role in the eventual discovery of ghrelin, the endogenous ligand of the growth hormone secretagogue receptor type 1a (GHS-R1a). Beginning in 1976, Bowers identified unnatural peptides capable of releasing GH through a mechanism distinct from growth hormone-releasing hormone (GHRH). These observations led to the hypothesis that the GHRPs reflected the activity of an unknown endogenous hormone, which was ultimately isolated from the stomach by Kojima and Kangawa in 1999 and named ghrelin. GHRP-2 thus occupies a unique position in endocrinology as both a research tool and a historical catalyst for the discovery of the ghrelin system.

Pharmacologically, GHRP-2 is distinguished from other GHRPs by its combination of high GH-releasing potency, moderate appetite stimulation, and activation of the hypothalamo-pituitary-adrenal (HPA) axis. In Japan, pralmorelin received regulatory approval as a diagnostic agent for GH deficiency under the designation KP-102D, based on its ability to reliably differentiate GH-deficient patients from healthy controls through a standardized GH provocation test. Beyond its neuroendocrine effects, GHRP-2 has attracted research interest for its anti-inflammatory, anti-catabolic, and cytoprotective properties observed in preclinical models of arthritis, burn injury, and acute lung injury.

Mechanism of Action

GHRP-2 exerts its primary effects through agonism of the growth hormone secretagogue receptor type 1a (GHS-R1a), a seven-transmembrane G-protein coupled receptor expressed at high density in the anterior pituitary somatotroph cells and in discrete hypothalamic nuclei, particularly the arcuate nucleus. Unlike GHRH, which acts via the GHRH receptor to stimulate GH synthesis and release through a cAMP-dependent pathway, GHRP-2 engages a distinct and complementary signaling cascade that involves multiple intracellular mediators.

Pituitary Signaling

At the pituitary level, GHRP-2 binding to GHS-R1a activates phospholipase C (PLC), leading to inositol triphosphate (IP3)-mediated release of intracellular calcium stores and subsequent GH exocytosis. Studies in bovine pituitary cells demonstrated that GHRP-2-stimulated GH release is dependent on extracellular calcium influx through voltage-dependent calcium channels, as the calcium channel blocker nifedipine abolished the response. Additionally, research in ovine somatotrophs revealed that GHRP-2, unlike GHRP-6, increases intracellular cAMP concentrations in a manner partially sensitive to GHRH receptor antagonism, suggesting a degree of cross-talk between the GHS-R1a and GHRH receptor signaling pathways in certain species.

The involvement of both protein kinase C (PKC) and cAMP/protein kinase A (PKA) pathways has been confirmed in multiple cell systems. In bovine pituitary cells, the PKC activator phorbol-12-myristate-13-acetate (PMA) and the cAMP-elevating agent forskolin each produced additive effects with GHRP-2 on GH release, indicating that GHRP-2 engages these pathways in parallel rather than sequentially.

Hypothalamic Actions

GHRP-2 also acts at the hypothalamic level, providing an amplification mechanism for GH release. Systemic administration of GHRP-2 (designated KP-102 in early studies) induces c-fos gene expression selectively in the ventromedial and ventrolateral regions of the arcuate nucleus, with double-label in situ hybridization revealing that approximately 23% of the c-fos-positive cells were GHRH neurons. This indicates that GHRP-2 activates a subpopulation of hypothalamic GHRH neurons, thereby increasing endogenous GHRH tone and creating a feed-forward loop that amplifies pituitary GH output.

This dual site of action (hypothalamus plus pituitary) underlies the powerful synergy observed when GHRP-2 and GHRH are co-administered. In healthy adult volunteers, Tiulpakov and colleagues demonstrated that the combined administration of GHRP-2 and GHRH produced a GH area-under-the-curve approximately 1.6 times that of GHRP-2 alone and 4.7 times that of GHRH alone, with GHRP-2 alone already exceeding the GH-releasing potency of GHRH by approximately threefold.

ACTH and Cortisol Stimulation

Beyond its effects on the somatotroph axis, GHRP-2 directly stimulates ACTH secretion and synthesis from corticotrope cells. Kageyama and colleagues demonstrated in mouse pituitary cell cultures that GHRP-2 increased ACTH release and proopiomelanocortin (POMC) mRNA expression through GHS-R1a-dependent activation of both PKA and PKC pathways. The GHRP-2-induced ACTH release was inhibited by the PKA inhibitor H89 and the PKC inhibitor bisindolylmaleimide I, while POMC transcription was sensitive only to PKA inhibition.

This property has been exploited diagnostically. The GHRP-2 stimulation test has been evaluated as an alternative to the insulin tolerance test (ITT) for assessing hypothalamo-pituitary-adrenal axis integrity, with a cortisol cut-off of 11.6 mcg/dL demonstrating 89.7% sensitivity and 88.9% specificity for secondary adrenal insufficiency.

Pharmacokinetics

The pharmacokinetic profile of GHRP-2 has been formally characterized in a Phase I study in prepubertal children with short stature conducted by Pihoker and colleagues. Following a single 1 mcg/kg intravenous dose, GHRP-2 disposition followed a biexponential (two-compartment) model.

Key Pharmacokinetic Parameters

The pharmacodynamic relationship between plasma GHRP-2 concentrations and GH output was well described by a sigmoid Emax model, enabling quantitative prediction of GH responses across dose ranges. The relatively rapid elimination (half-life of approximately 33 minutes) supports the observed pattern of acute, pulsatile GH release followed by return to baseline within 2 hours.

Oral Bioavailability

GHRP-2 is orally active, a property that distinguishes it from many bioactive peptides. Clinical studies in normal children demonstrated that oral GHRP-2 stimulated GH secretion with onset at approximately 15 minutes, peak at 60 minutes, and return to baseline by 180 minutes. The oral GH-releasing activity has been confirmed across species and was a key factor in the development of non-peptide GHS mimetics.

Continuous Infusion Dynamics

In a 24-hour continuous intravenous infusion study (1 mcg/kg/h) in postmenopausal women, GHRP-2 elicited a 7.7-fold increase in mean 24-hour serum GH concentrations, a 7.1-fold augmentation of GH secretory burst mass, and a 10-fold rise in GH burst amplitude, without altering GH pulse frequency, interpulse interval, or calculated GH half-life. Fasting IGF-1 concentrations rose by 102 +/- 18 mcg/L over the infusion period. Serum prolactin and cortisol were modestly but significantly elevated.

Research Applications

Growth Hormone Secretion and Diagnostics

The primary research application of GHRP-2 has been as a tool for investigating the regulation of pulsatile GH secretion. In comparative studies with GHRH, GHRP-2 consistently produces a greater magnitude of GH release when administered alone and a synergistic response when combined with GHRH. This synergy has been attributed to the complementary mechanisms of the two peptides: GHRP-2 amplifies GH secretory burst mass and amplitude through GHS-R1a while GHRH increases the readily releasable GH pool through the GHRH receptor.

Studies in older adults with age-related decline in GH secretion have demonstrated that chronic subcutaneous infusion of GHRP-2 (1 mcg/kg/h for 30 days) increased pulsatile GH secretion and elevated serum IGF-1 levels, with the effect maintained throughout the treatment period without evidence of tachyphylaxis.

In Japan, the GHRP-2 stimulation test (using pralmorelin as KP-102D) has been developed as a standardized diagnostic tool for GH deficiency. The test is based on the observation that GH-deficient patients exhibit a markedly attenuated GH response to GHRP-2 compared to healthy controls. Receiver operating characteristic analysis established a peak GH cut-off of 15 mcg/L for discriminating between GH-deficient and GH-sufficient individuals.

Appetite Regulation and Food Intake

As a ghrelin receptor agonist, GHRP-2 recapitulates the orexigenic effects of ghrelin. Laferrere and colleagues conducted the first controlled study of GHRP-2’s effects on food intake in humans. Seven lean, healthy males received subcutaneous infusion of GHRP-2 (1 mcg/kg/h) or saline for 270 minutes, followed by an ad libitum buffet meal. Subjects infused with GHRP-2 consumed 35.9% more food than during saline infusion (136.0 kJ/kg versus 101.3 kJ/kg, p = 0.008), with every subject increasing intake. The macronutrient composition of consumed food did not differ between conditions.

In a longer-term study, Mericq and colleagues administered oral GHRP-2 (900 mcg/kg twice daily) to ten GH-deficient children for 12 months. Seven of ten patients reported significantly increased appetite during the first 6 months. However, the appetite-stimulating effect appeared to attenuate over time, and BMI did not change significantly during the treatment period, suggesting possible tolerance to the orexigenic effect during chronic administration.

Anti-Inflammatory and Cytoprotective Effects

A growing body of preclinical evidence demonstrates that GHRP-2 possesses significant anti-inflammatory properties that extend beyond its neuroendocrine actions. In adjuvant-induced arthritic rats, GHRP-2 administration (100 mcg/kg/day for 8 days) ameliorated external symptoms of arthritis, decreased the arthritis score, and reduced paw volume. Circulating IL-6 levels were significantly reduced. Importantly, both GHRP-2 and ghrelin (at 10^-7 M) directly inhibited endotoxin-induced IL-6 and nitrite/nitrate release from peritoneal macrophages in vitro, demonstrating a direct anti-inflammatory action on immune cells mediated through ghrelin receptors.

In a lipopolysaccharide (LPS)-induced acute lung injury model, pretreatment with GHRP-2 (100 mcg/kg subcutaneous) attenuated lung tissue injury, reduced pulmonary edema, decreased neutrophil infiltration, and lowered bronchoalveolar levels of TNF-alpha and IL-6. The mechanism was associated with suppression of NF-kappaB activation in lung tissues, suggesting that GHRP-2’s anti-inflammatory effects are at least partly mediated through inhibition of this central inflammatory transcription factor.

Skeletal Muscle Protection and Anti-Catabolic Effects

GHRP-2 has demonstrated direct anti-catabolic effects on skeletal muscle through suppression of the ubiquitin-proteasome proteolytic pathway. In burn injury models, continuous GHRP-2 infusion over 24 hours attenuated the injury-induced upregulation of the E3 ubiquitin ligases MuRF-1 and MAFbx (also known as Atrogin-1), key mediators of muscle protein degradation. Furthermore, GHRP-2 reduced IL-6 expression in skeletal muscle and attenuated both total and myofibrillar protein breakdown in extensor digitorum longus muscle preparations.

Critically, Yamamoto and colleagues demonstrated that these anti-catabolic effects are not solely GH-mediated but involve direct action on skeletal muscle cells. In differentiated C2C12 myocytes, GHRP-2 dose-dependently attenuated dexamethasone-induced expression of Atrogin-1 and MuRF1, and this effect was blocked by [D-Lys3]-GHRP-6, a specific GHS-R1a antagonist. GHRP-2 did not influence plasma IGF-1 levels or muscular IGF-1 mRNA in vivo, confirming that the anti-atrophic effect occurs through direct GHS-R1a-mediated signaling in myocytes rather than through the GH-IGF-1 axis.

In arthritis models, the same protective effect on muscle was confirmed: GHRP-2 prevented the arthritis-induced increase in MuRF1, MAFbx, and TNF-alpha gene expression in skeletal muscle while increasing hepatic IGF-1 expression and circulating IGF-1 levels.

Critical Illness and Metabolic Recovery

Van den Berghe and colleagues investigated combined GHRP-2 and TRH (thyrotropin-releasing hormone) infusion in critically ill patients with protracted illness characterized by protein wasting and suppressed pulsatile GH and TSH secretion. Five-day continuous infusion of GHRP-2 plus TRH (1 + 1 mcg/kg/h) reactivated pulsatile GH and TSH secretion with preserved feedback inhibition, elevated IGF-1 and GH-dependent binding proteins to near-normal levels from day 2 onward, and induced a measurable shift toward anabolic metabolism as indicated by increased osteocalcin (19% versus -6% with placebo), increased leptin (32% versus -15%), and reduced protein degradation.

Safety Profile

The safety data for GHRP-2 are derived primarily from acute and short-term studies in both animal models and limited human investigations. No formal long-term toxicology studies comparable to those required for therapeutic drug approval have been published, though the available evidence suggests a generally favorable safety profile at research-relevant doses.

Endocrine Effects

The most consistent secondary endocrine effects of GHRP-2 are modest elevations of ACTH, cortisol, and prolactin. In the 24-hour infusion study by Shah and colleagues, pooled daily cortisol increased from 5.3 to 7.0 mcg/dL and prolactin from 6.8 to 12 mcg/L during GHRP-2 infusion (both p < 0.05), while LH, FSH, and TSH remained unchanged. These effects are considered more pronounced than those of ipamorelin (which is regarded as the most GH-selective secretagogue) but less pronounced than those of GHRP-6. The clinical significance of modest cortisol elevation during chronic GHRP-2 administration has not been systematically evaluated.

Appetite Stimulation

The orexigenic effect of GHRP-2 represents a pharmacological action that may be either desirable or undesirable depending on the research context. In the long-term oral dosing study in children, appetite stimulation appeared to attenuate after 6 months without producing significant body weight gain.

Reported Adverse Effects

In published clinical studies, GHRP-2 has been generally well tolerated. No serious adverse events attributable to GHRP-2 have been reported in the peer-reviewed literature. Transient flushing at the injection site and mild gastrointestinal discomfort have been noted in some subjects receiving subcutaneous or intravenous administration.

Dosing in Research

The following table summarizes dosing parameters from key published GHRP-2 studies across various models and experimental paradigms.

Molecular Properties

Storage and Handling

GHRP-2 should be stored as lyophilized powder at -20 degrees Celsius for long-term stability, where it typically remains stable for 2 or more years. The lyophilized peptide should be protected from light, moisture, and repeated temperature fluctuations. Allow vials to equilibrate to room temperature before opening to prevent moisture condensation on the peptide cake.

For reconstitution, bacteriostatic water is the preferred solvent for research applications. Direct the solvent stream against the vial wall rather than onto the peptide cake, and gently swirl until dissolved. Do not vortex. A clear, colorless solution with no visible particulates confirms successful reconstitution. Typical reconstitution concentrations range from 1 to 5 mg/mL.

Once reconstituted, GHRP-2 solutions should be stored at 2-8 degrees Celsius and used within 30 days. For extended storage of reconstituted material, aliquot into single-use volumes and store at -20 degrees Celsius. Avoid repeated freeze-thaw cycles, as these may promote peptide aggregation and loss of biological activity. Verify peptide integrity periodically using reversed-phase HPLC or mass spectrometry where available.

Current Research Landscape

GHRP-2 occupies a well-established position in GH secretagogue research, with a literature spanning more than three decades. Several directions are shaping the current and future research landscape.

Ghrelin system biology: GHRP-2 continues to serve as a valuable pharmacological tool for dissecting the physiology of the ghrelin/GHS-R1a system. Its selectivity for GHS-R1a, combined with its well-characterized pharmacokinetics, makes it a reference compound for studying ghrelin receptor-mediated signaling in both central and peripheral tissues. The identification of GHS-R1a expression on immune cells, myocytes, and various other cell types continues to expand the known scope of GHRP-2’s direct actions.

Anti-catabolic and muscle-sparing applications: The demonstration that GHRP-2 directly suppresses muscle-specific ubiquitin ligases through GHS-R1a on myocytes, independently of the GH-IGF-1 axis, has opened a significant research avenue. These findings suggest potential utility in catabolic conditions where GH therapy alone may be insufficient, including burn injury, sepsis-associated myopathy, glucocorticoid-induced atrophy, and age-related sarcopenia. The 2025 study by Li and colleagues demonstrating enhanced tendon-bone healing in a rotator cuff repair model further expands the musculoskeletal research applications.

Diagnostic standardization: The GHRP-2 test for GH deficiency and secondary adrenal insufficiency continues to be refined as clinical diagnostic data accumulate, particularly in Japan where pralmorelin is an approved diagnostic agent. Ongoing research aims to better define optimal cut-off values across different patient populations and to compare the GHRP-2 test with established provocative tests.

Anti-inflammatory therapeutics: The convergent evidence from arthritis, acute lung injury, ovarian granulosa cell, and burn injury models positions GHRP-2 as a prototype for ghrelin agonist-based anti-inflammatory strategies. The identification of specific signaling pathways (NF-kappaB suppression, MKP-1 and PP2A involvement) provides a mechanistic foundation for rational development of next-generation compounds.

Combination neuroendocrine strategies: The work by Van den Berghe and colleagues on GHRP-2 plus TRH in critical illness demonstrated the concept of combined secretagogue therapy to reactivate suppressed pituitary axes. This approach represents a conceptually distinct strategy from exogenous hormone replacement and warrants further investigation in catabolic states.

References

The references for this monograph are listed in the frontmatter metadata and rendered automatically by the site template. All citations correspond to peer-reviewed publications indexed in PubMed with verifiable DOIs.